

**PB 103 of 2021**

National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 7)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 September 2021

**NIKOLAI TSYGANOV**

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) 2

1 Name

 This instrument is the *National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 7).*

This instrument may also be cited as PB 103 of 2021.

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 October 2021. |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 85AB(1) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1 Schedule 1, after item dealing with Brivaracetam

insert:

Brolucizumab

2 Schedule 1, after item dealing with Darbepoetin alfa

omit:

Darunavir

3 Schedule 1, after item dealing with Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain

omit:

Nadroparin

4 Schedule 1, after item dealing with Natalizumab

omit:

Nedocromil

5 Schedule 1, after item dealing with Nilotinib

omit:

Nilutamide

6 Schedule 1, after item dealing with Ocriplasmin

insert:

Ofatumumab

7 Schedule 1, after item dealing with Sulthiame

omit:

Sunitinib

8 Schedule 1, after item dealing with Terbutaline

omit:

Teriparatide

9 Schedule 2, after item dealing with Cefalexin

omit:

Cefalotin

10 Schedule 2, after item dealing with Ciclosporin

omit:

Cimetidine

11 Schedule 2, after item dealing with Cyproterone

insert:

Darunavir

12 Schedule 2, after item dealing with Sumatriptan

insert:

Sunitinib

13 Schedule 2, after item dealing with Teriflunomide

insert:

Teriparatide